AccScience Publishing / IMO / Online First / DOI: 10.36922/IMO026270051
Cite this article
1
Download
83
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

The tumor as a dynamic metabolic interaction network: From the Warburg effect to multi-node collapse as a therapeutic strategy

Serhii Khablak1* ,  Lesia Bondareva2 ,  Yana Abdullaieva3 ,  Valentyn Spychak1
Show Less
1 Institute of Food Biotechnology and Genomics, National Academy of Sciences of Ukraine, Kyiv , Ukraine
2 National University of Life and Environmental Sciences of Ukraine, Kyiv , Ukraine
3 Rozkom LLC, Kyiv , Ukraine
Received: 1 July 2026 | Revised: 21 October 2026 | Accepted: 22 October 2026 | Published online: 17 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Cancer metabolism research has long been shaped by a pathway-centric paradigm, in which individual biochemical routes—most prominently aerobic glycolysis (the Warburg effect)—are studied and targeted in relative isolation. Accumulating evidence from systems biology, multi-omics profiling, and computational oncology suggests, however, that this view is insufficient to explain the adaptive resilience that solid tumors routinely demonstrate against metabolic inhibitors. Here we propose a conceptual synthesis: the tumor dynamic metabolic interaction network, a graph-theoretic framework in which metabolic enzymes and transporters constitute nodes, substrate fluxes define weighted edges, and the system’s overall state is governed by topological properties such as betweenness centrality and eigenvector centrality. Within this framework, we elaborate the hypothesis of dynamic network collapse (DNC)—the notion that simultaneous perturbation of several high-centrality nodes may push the tumor metabolic network beyond a thermodynamic instability threshold, triggering irreversible functional disintegration that cannot be escaped through known compensatory rerouting. We review the three dominant metabolic axes of tumor survival—glucose (GLUT1/HK2/PKM2), glutamine (SLC1A5/GLS1), and lactate efflux (MCT1/MCT4)—and examine how each contributes to immunosuppression through metabolic competition with cytotoxic T lymphocytes and through the acidification of the tumor microenvironment. We further discuss genome-scale metabolic models, flux balance analysis, and graph neural network approaches that may render the DNC concept computationally actionable. The clinical implications of multi-node targeting are considered alongside the limitations of existing evidence and unresolved methodological challenges. Although the DNC hypothesis remains to be tested experimentally in relevant in vivo models, it provides a coherent rationale for the next generation of combination metabolic therapies and for patient-specific metabolic profiling as a decision tool.

Keywords
Cancer metabolism
Warburg effect
Tumor microenvironment
Metabolic network
MCT1/MCT4
Glutaminolysis
Immunometabolism
Dynamic network collapse
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors declare no conflicts of interest.
References
  1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi: 10.1126/science.1160809
  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
  3. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218. doi: 10.1016/j.tibs.2015.12.001
  4. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi: 10.1126/sciadv.1600200
  5. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619-634. doi: 10.1038/nrc.2016.71
  6. Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411(6833):41-42. doi: 10.1038/35075138
  7. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. doi: 10.1038/nrg2918
  8. Lee DS, Park J, Kay KA, et al. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA. 2008;105(29):9880-9885. doi: 10.1073/pnas.0802208105
  9. Thiele I, Swainston N, Fleming RM, et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013;31(5):419-425. doi: 10.1038/nbt.2488
  10. Robinson JL, Kocabaş P, Wang H, et al. An atlas of human metabolism. Sci Signal. 2020;13(624):eaaz1482. doi: 10.1126/scisignal.aaz1482
  11. Folger O, Jerby L, Frezza C, et al. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011;7:501. doi: 10.1038/msb.2011.35
  12. Jerby L, Wolf L, Denkert C, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 2012;72(22):5712-5720. doi: 10.1158/0008-5472.CAN-12-2215
  13. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási AL. Hierarchical organization of modularity in metabolic networks. Science. 2002;297(5586):1551-1555. doi: 10.1126/science.1073374
  14. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213-228. doi: 10.1016/j.ccr.2013.06.014
  15. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73. doi: 10.1126/scisignal.2000431
  16. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350. doi: 10.1073/pnas.0709747104
  17. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762-765. doi: 10.1038/nature07823
  18. Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in cancer and their relevance to ‘glutamine addiction’: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782-1788. doi: 10.1158/0008-5472.CAN-14-3745
  19. Momcilovic M, Bailey ST, Lee JT, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002
  20. Halestrap AP, Wilson MC. The monocarboxylate transporter family—role and regulation. IUBMB Life. 2012;64(2):109-119. doi: 10.1002/iub.607
  21. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial ‘lactate shuttle’ in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle. 2011;10(11):1772-1783. doi: 10.4161/cc.10.11.15659
  22. Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011
  23. Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151-161. doi: 10.1038/s41577-020-0406-2
  24. Halford SER, Veal GJ, Wedge SR, et al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29(8):1429-1439. doi: 10.1158/1078-0432.CCR-22-2263
  25. Xu Z, Wang X, Cheng H, Li J, Zhang X, Wang X. The role of MCT1 in tumor progression and targeted therapy: a comprehensive review. Front Immunol. 2025;16:1610466. doi: 10.3389/fimmu.2025.1610466
  26. Benjamin D, Robay D, Hindupur SK, et al. Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep. 2018;25(11):3047-3058.e4. doi: 10.1016/j.celrep.2018.11.043
  27. Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229-1241. doi: 10.1016/j.cell.2015.08.016
  28. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155):1242454. doi: 10.1126/science.1242454
  29. Huang Y, Mohanty V, Dede M, et al. Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nat Commun. 2023;14(1):4883. doi: 10.1038/s41467-023-40457-w
  30. Ho PC, Bihuniak JD, Macintyre AN, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162(6):1217-1228. doi: 10.1016/j.cell.2015.08.012
  31. Lv H, Wu X, Zhang X, et al. Glutamine: a new strategy for targeted metabolic therapy in the tumor microenvironment. Cell Death Discov. 2025;11:459. doi: 10.1038/s41420-025-02767-4
  32. Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381-1390. doi: 10.1158/0008-5472.CAN-15-1743
  33. Bola BM, Chadwick AL, Michopoulos F, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13(12):2805-2816. doi: 10.1158/1535-7163.MCT-13-1091
  34. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887-904. doi: 10.1038/nrd.2018.169
  35. Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247-250. doi: 10.1038/nature24297
  36. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Science. 2013;339(6116):1336-1340. doi: 10.1126/science.1238426
  37. Sousa CM, Biancur DE, Wang X, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536(7617):479-483. doi: 10.1038/nature19084
  38. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162(3):540-551. doi: 10.1016/j.cell.2015.07.016
  39. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869-874. doi: 10.1038/ng.890
  40. Lewis JE, Forshaw TE, Boothman DA, Furdui CM, Kemp ML. Personalized genome-scale metabolic models identify targets of redox metabolism in radiation-resistant tumors. Cell Syst. 2021;12(1):68-81.e11. doi: 10.1016/j.cels.2020.12.001
  41. Zielinski DC, Jamshidi N, Corbett AJ, et al. Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. Sci Rep. 2017;7:41241. doi: 10.1038/srep41241
  42. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2010;107(5):2037-2042. doi: 10.1073/pnas.0914433107
  43. Qing G, Li B, Vu A, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012;22(5):631-644. doi: 10.1016/j.ccr.2012.09.021
  44. Gogoshin G, Rodin AS. Graph neural networks in cancer and oncology research: emerging and future trends. Cancers. 2023;15(24):5858. doi: 10.3390/cancers15245858
  45. Liu M, Srivastava G, Ramanujam J, Brylinski M. SynerGNet: a graph neural network model to predict anticancer drug synergy. Biomolecules. 2024;14(3):253. doi: 10.3390/biom14030253
  46. Sullivan MR, Danai LV, Lewis CA, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife. 2019;8:e44235. doi: 10.7554/eLife.44235
  47. Tanıl E, Nikerel E. Multi-omic data integration and exploiting metabolic models using systems biology approach increase precision in subtyping and early diagnosis of cancer. Quant Biol. 2025;13(4):e70012. doi: 10.1002/qub2.70012
  48. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. doi: 10.1126/science.aan4236
Share
Back to top
Innovative Medicines & Omics, Electronic ISSN: 3060-8740 Print ISSN: 3060-8910, Published by AccScience Publishing